SHANGHAI FOSUN PHARMACEUTICAL (GROUP)
SSE or SZSE Delayed Price. Currency in CNY
|Number of Shares|
|Company Name||SHANGHAI FOSUN PHARMACEUTICAL (GROUP)|
|MSCI Security Code|
- Aug 31 , 2018
Fosun Is Probing Report of Pharma Unit’s Fraud, Chairman SaysA unit of Shanghai Fosun Pharmaceutical Group that makes generic drugs has been charged with raw materials fraud and other irregularities. Fosun Pharma is conscious of the seriousness of the report and is conducting strict on-site investigations to verify the situation, according to its chairman.
- Aug 31 , 2018
Fosun Pharma Makes Fake APIs, Production Reports, Employee SaysLeaders of a research unit of Fosun Pharmaceutical push workers to fabricate a large amount of production and inspection reports so as to hide the fact that the firm fails to follow the standards for almost all active pharmaceutical ingredients, one of the employees has claimed.
- Jan 11 , 2018
Fosun Pharma Announces Plan to Up Innovation at Home, AbroadShanghai Fosun Pharmaceutical (Group) Co. [SHA:600196] will contribute CNY102 million (USD15.6 million) to its subsidiary, Shanghai Futuo Biotech Development Co., and will join hands with Fosun International Ltd. [HK:0656] to invest USD50 million to establish a new US company.
- Jan 3 , 2018
More Chinese Firms Apply to Conduct Clinical Trials of CAR-T Therapies as China Edges Forward in BiotechnologyChina’s food and drug regulator, the China Food and Drug Administration, has accepted an application by Anhui-based biopharmaceutical company Anke Biotechnology (Group) Co. [SHE:300009] to conduct clinical trials of chimeric antigen receptor-T (CAR-T) therapies. Five Chinese firms applied to test CAR-T therapies last month as China edges ahead of Europe in the field.
- Dec 29 , 2017
Fosun Pharma Plans a Large-Scale Industrial Park in JiangsuHuge pharmaceutical conglomerate Fosun Pharma is planning to build a large-scale industrial park and a new headquarters building in Xuzhou in China’s east-central Jiangsu province.
- Dec 19 , 2017
China’s Home-Grown Cell Therapy Expected to Get Approval in Three Years Will Drop Treatment Costs, Says InsiderChina’s independently-developed first chimeric antigen receptor-T (CAR-T) cell may get approval in three years, and prices could fall below CNY100,000 (USD15,130) to make such therapy more affordable, a Chinese industry insider told Yicai Global.
- Dec 18 , 2017
Chinese CAR-T Products Priced Below USD15,130 May Hit Market in Three Years, Insider SaysChina’s first home-grown chimeric antigen receptor T-cell immunotherapy may get the go-ahead from national regulators in three years, and the price of CAR-T products will drop, perhaps below CNY100,000 (USD15,130), a market insider told Yicai Global.
- Oct 30 , 2017
Fosun Pharmaceutical Plans to Buy Tridem Pharma for USD73 MillionChinese drug industry titan Shanghai Fosun Pharmaceutical Group Co. [SHA:600196] plans to acquire a French firm for USD73 million (EUR63 million). The latter is the third largest pharmaceutical distribution company in the French-speaking region of West Africa.
- Sep 18 , 2017
Fosun Pharmaceutical to Buy 74% Stake in Indian Firm in Revised USD1 Billion OfferShanghai Fosun Pharmaceutical Group Co. [SHA:600196], an arm of Chinese investment company Fosun International Ltd. [HKG:0656], has agreed a revised deal worth USD1.09 billion (CNY7.14 billion) to acquire 74-percent stake in Indian drug company Gland Pharma Ltd. from private equity firm KKR and Co. LP, the conglomerate said in a statement on Sept. 17.
- Sep 12 , 2017
CFDA Policies Won’t Affect Fosun Pharma’s Plan to Bring Overseas CAR-T Therapies to China, CEO SaysShanghai Fosun Pharmaceutical Group Co. [SHA:600196] does not expect government policy to hinder its introduction of foreign biological cellular immune (CAR-T) therapies to China, online media outlet The Paper reported, quoting Wu Yifang, chief executive.
- Sep 1 , 2017
HK Subsidiary of Fosun Pharma Splurges USD66.5 Million on Drug Firm Share PurchaseA Hong Kong-based wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. [SHA:600196] recently purchased a stake in a pharmaceutical research and development company on the Nasdaq Stock Market.
- Aug 17 , 2017
Fosun Pharma and Medidata Reach a Cooperation Agreement to Improve Efficiency in Clinical StudiesChinese healthcare group Shanghai Fosun Pharmaceutical (Group) Co. [SHA:600196] and Medidata Solutions Inc., a world-leading global medical software company, reached a cooperation agreement to raise the operational efficiency of its clinical studies in China.
- Aug 14 , 2017
Shanghai Pharmaceuticals Plans Bid for Stake in US Drug Maker ArborTwo leading Chinese pharmaceutical companies have announced their bid intention to buy into US drug maker Arbor Pharmaceuticals LLC.
- Jul 21 , 2017
One Month After A-Shares Inclusion Into MSCI, 70% of 222 Concept Stocks Rise, 20 Hit New HighIn the small hours of June 21, MSCI announced its decision to incorporate China’s A-shares into the MSCI Emerging Markets Index.